Cytoprotective effect of TRK-100, a prostacyclin analogue, against chemical injuries in cultured human vascular endothelial cells.
We studied the cytoprotective effect of TRK-100, a chemically stable analogue of prostacyclin (PGI2), in the cultured human endothelial cells from umbilical vein. TRK-100 (10 and 100 nM) stimulated significantly proliferation of endothelial cells but did not affect PGI2 production in endothelial cells. Exposure of cultured endothelial cells to homocysteine (2.5 mM) or glucose (50 mM) caused concentration-dependent cytotoxicity, as evidenced by a decrease in number of viable cells. When endothelial cells were treated with TRK-100 simultaneously or prior to, but not after, exposure to injury substances, decreases in viable cell were significantly suppressed. The protective effect of TRK-100 against homocysteine-induced cytotoxicity also appeared in endothelial cells treated with acetylsalicylic acid, suggesting that endogenous PGI2 did not involve in the protective effect of TRK-100.
Sakai
A
A
Central Research Institute, Kaken Pharmaceutical Co., Ltd., Kyoto, Japan.
Yajima
M
M
Nishio
S
S
D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects*; D011464:Epoprostenol / Q000096:biosynthesis / Q000494:pharmacology* / Q000031:analogs & derivatives; D005947:Glucose / Q000037:antagonists & inhibitors / Q000633:toxicity; D006710:Homocysteine / Q000037:antagonists & inhibitors / Q000633:toxicity; D006801:Humans; D009130:Muscle, Smooth / Q000187:drug effects; D011460:Prostaglandins F / Q000378:metabolism; D011465:Prostaglandins, Synthetic / Q000494:pharmacology
D011460:Prostaglandins F; D011465:Prostaglandins, Synthetic; D006710:Homocysteine; C048081:beraprost; D011464:Epoprostenol; D005947:Glucose; C100006:prostaglandin F1